Hopf China subscription

Hefu China 2022 February 8 subscription, the total number of shares issued 99.51 million shares, of which 39.81 million shares were issued online, the issuance of P/E ratio of 22.99 times. Subscription code 732122, subscription price of 4.19 yuan, a single account subscription limit of 39,000 shares, the company's main in vitro diagnostic reagents research and development, production and sales. Hopf China this fund-raising after deducting the issue costs, will be used for medical testing intensive marketing and edema high-tech instrument introduction project, information technology upgrading and medical management exchange center project, supplementary working capital. After the completion of the IPO, the new shares are usually listed and traded after 8-14 days (natural days), and the listing time of Hefei China will be around Jan. 19, 2022 to Jan. 25, 2022, the company said.

On Oct. 24, 2000, Hopefluent (China) Medical Technology Corp. was established.

On December 24, 2021, the "SEC Releases" public news, the Securities and Futures Commission in accordance with the statutory procedures approved the application for the initial public offering of the Hofu (China) Medical Technology Company Limited, and the enterprise and its underwriters will consult with the Exchange to determine the issuance schedule and publish the prospectus document.

On February 16, 2022, Hopefluent (China) Medical Technology Co. was listed on the main board of the Shanghai Stock Exchange.

The company's scope of business includes: international trade mainly in machinery and equipment and their consumables, re-export trade and after-sales service for the products it sells, trade and trade agency between enterprises in the region, commercial simple processing in the region, consulting services for hospital information management systems, medical equipment, medical devices, and related accessories and reagents, pharmaceuticals, chemical raw materials and products (excluding hazardous chemicals and explosives);

Hefu (China) Medical Technologies Co.

Wholesale, commission agency (except auction), import and export business of computers, software and auxiliary equipments, hardware and electronic products, mechanical equipments and accessories, instruments and meters, electromechanical equipments and accessories, as well as provision of related ancillary services and related consulting services, operational leasing of medical equipments, domestic road transportation of general cargo, and engaging in the development of medical science and technology (except human stem cells), gene diagnosis and treatment technology.

Hopeful China is a channel provider in the medical distribution field, and has the core competence of long-term reciprocal and win-win cooperation*** with domestic and foreign reagent and consumable and medical equipment manufacturers, major agents and medical institutions.

The controlling shareholder of the Company is Hopefluent Hong Kong, which holds 73.34% of the Company's shares; during the reporting period, there was no actual controller who can actually dominate the Company's behavior through investment relationship, agreement or other arrangements.

Hopeful China's proceeds, after deduction of issuance costs, will be used for the introduction of medical testing intensive marketing and edema high-tech instrumentation project, information technology upgrading and medical management exchange center project, and supplementary working capital.